Media stories about Nivalis Therapeutics (NASDAQ:ALPN) have trended somewhat negative this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Nivalis Therapeutics earned a news impact score of -0.04 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.3577083667169 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Shares of Nivalis Therapeutics (NASDAQ:ALPN) opened at 8.63 on Friday. The company’s market cap is $11.56 million. Nivalis Therapeutics has a 12-month low of $7.20 and a 12-month high of $37.40. The firm’s 50-day moving average price is $8.86 and its 200 day moving average price is $9.74.

A number of equities analysts recently weighed in on ALPN shares. Zacks Investment Research cut Nivalis Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 10th. ValuEngine cut Nivalis Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, August 2nd. Finally, Ladenburg Thalmann Financial Services started coverage on Nivalis Therapeutics in a research report on Thursday, July 27th. They issued a “buy” rating and a $17.00 price objective on the stock. Two research analysts have rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company. Nivalis Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $7.79.

TRADEMARK VIOLATION WARNING: “Nivalis Therapeutics (ALPN) Receives Daily News Sentiment Rating of -0.04” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at

In other news, insider Value Fund L. P. Biotechnology acquired 17,806 shares of the stock in a transaction that occurred on Tuesday, June 20th. The shares were bought at an average cost of $2.25 per share, for a total transaction of $40,063.50. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Bvf Partners L. P/Il acquired 35,750 shares of the stock in a transaction that occurred on Monday, June 5th. The stock was purchased at an average price of $2.29 per share, for a total transaction of $81,867.50. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 163,106 shares of company stock valued at $372,432. 9.80% of the stock is owned by company insiders.

About Nivalis Therapeutics

Nivalis Therapeutics, Inc is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.

Receive News & Ratings for Nivalis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.